You are here

Low-Dose MRI-Compatible Molecular Breast Imaging Device

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA176961-01
Agency Tracking Number: R43CA176961
Amount: $142,432.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA12-088
Timeline
Solicitation Year: 2013
Award Year: 2013
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
700 Michigan Avenue Suite 200
BUFFALO, NY 14203-
United States
DUNS: 783523306
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL ZWICK
 (716) 856-3873
 michael.zwick@empiregenomics.com
Business Contact
 MICHAEL XWICK
Phone: (716) 856-3873
Email: michael.zwick@empiregenomics.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Multiple myeloma is a malignant plasma cell cancer that is increasing in frequency in today's aging population. While new combination therapies have improved the outcome of treatment, many patients fail to achieve a complete remission and ultimately the disease progresses. With these new treatments come higher associated toxicities and significant healthcare costs for the drugs. Proteasome inhibitors are frequently used as one of the treatments for multiple myeloma, withbortezomib (Velcade) approved in 2003 and carfilzomib (Kyprolis- Onyx Pharmaceuticals) approved in July 2012. For several new cancer therapies such as Zelboraf and palkori, companion diagnostics were approved in parallel with the drug to guide physiciansin selecting those patients who would benefit from the drug. Unfortunately no such test exists for multiple myeloma, and the associated drug costs and side effects are quite significant. We have discovered a genetic mutation associated with the response tobortezomib. This would be an extremely useful test for physicians to guide treatment of patients and would be useful to stratify patients in clinical trials for next generatin proteasome inhibitors. The goals of this Phase I proposal are to optimize the test using samples already examined by our academic collaborator and develop positive and negative controls for this assay. We also propose to sequence the region involved in this translocation to better understand the disease. Future work envisioned in a Phase II would be to increase the number of clinical samples and sites, test for utility in guiding use of other proteasome inhibitors, and expand into other cancers where proteasome inhibitors have been approved or are in clinical trials. Successful development of this assay would have commercial significance, reduce the cost of health care, and provide benefit to patients while increasing the success in the drug development industry with better selection of patients in clinical trials. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Empire Genomics is seeking funding to develop a companion diagnostic test for multiple myeloma. This disease accounts for approximately 10% of the blood based cancers, with a prediction of 21,700 new cases and 10,710 deaths in the US in 2012. While advances in therapeutic treatments have improved the response rate, there are significant side effects to these costly treatments. A companion diagnostic that guides treatment would save health care costs and spare patients the deleterious consequences of treatments that will not be effective.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government